CADILA PHARMACEUTICALS LTD

Ahmedabad-based Cadila Pharmaceuticals generated a revenue of Rs 41 crore during FY 20-21 in the biopharma space, exhibiting a humongous growth of 136 per cent as compared to Rs 17 crore worth revenue generated in FY 19-20. The company announced the launch of NuPTH, an osteoporosis biosimilar of Forteo in India, for the treatment of osteoporosis and in patients with increased risk of fracture. Cadila also launched biosimilar Rituximab for the Indian market in 2020, used for treatment of blood cancer and rheumatoid arthritis. It was launched under the brand name Ritucad. Adalimumab biosimilar under the brand name Cadalimab for arthritis was also launched during FY 20-21.